Bio

Eric Greig advises clients on market access and reimbursement strategies across the medical device, pharmaceutical, digital health, biotechnology, clinical laboratory, and healthcare services sectors. Mr. Greig also advises private equity firms, investment banks, venture capital funds, commercial lenders, and healthcare and life science companies on regulatory issues related to mergers and acquisitions, IPOs, and US financings. Mr. Greig is a member of the American Health Law Association and the American Bar Association Health Law Section. A recognized thought leader, Mr. Greig regularly writes and speaks on healthcare and life sciences topics. He co-authored a chapter related to Medicare and Medicaid reimbursement for off-label uses of drugs and devices in Off-Label Communications: A Guide to Sales & Marketing Compliance, published by the Food and Drug Law Institute (FDLI), and presents on healthcare regulatory and reimbursement topics at national conferences organized by leading industry organizations including AdvaMed, PhRMA, the American Health Law Association (AHLA), the Medical Device Manufacturers Association (MDMA), the 8400 Health Network, and the California Life Sciences Institute.